Article
Novartis' Sandoz targets biosimilar version of J&J drug in Samsung deal
Rating:
0.0
Views:
74
Likes:
1
Library:
1
Novartis' generic-drugs unit Sandoz said on Monday it plans to launch a generic version of Johnson & Johnson's anti-inflammatory drug Stelara under a collaboration deal with Samsung Bioepis.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value